Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,451 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 4,000 · Balance 21,451 F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.74 · Expires 2036-01-01 | Direct | 3,475 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 3,475 · Balance 3,475 F2: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027.
F2: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2020 Filed Apr 21, 2020 20:13 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 8,147 | $50.58 | $412,042.67 |
DisclosureSEC source: 0001070081-20-000083 · wf-form4_158749998486296.xml · nonDerivative · entry 4 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,251 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2020. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.01 to $51.00 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 20:13 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 17,900 | $10.85 | $194,215.00 |
DisclosureSEC source: 0001070081-20-000083 · wf-form4_158749998486296.xml · nonDerivative · entry 3 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2020. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 20:13 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 2,100 | $10.85 Strike: $10.85 | $22,785.00 |
DisclosureSEC source: 0001070081-20-000083 · wf-form4_158749998486296.xml · derivative · entry 7 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,900 Underlying: Common Stock · 2,100 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2020. F5 · derivative.exercise_date: Currently exercisable. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 20:13 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,100 | $50.16 | $105,331.80 |
DisclosureSEC source: 0001070081-20-000083 · wf-form4_158749998486296.xml · nonDerivative · entry 2 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,498 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2020. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to $50.37 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 20:13 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,100 | $10.85 | $22,785.00 |
DisclosureSEC source: 0001070081-20-000083 · wf-form4_158749998486296.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2020. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:39 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $51.16 | $0.00 |
DisclosureSEC source: 0001070081-20-000045 · wf-form4_158050674128984.xml · derivative · entry 2 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-01-28 F2 · derivative.exercise_date: This option was granted on January 29, 2020 and vests over one year in twelve equal monthly installments, commencing on February 29, 2020. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:39 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-20-000045 · wf-form4_158050674128984.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,498 F1 · shares: Restricted stock units ("RSUs") granted on January 29, 2020 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 10, 2020 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 29, 2021. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:47 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001104659-19-003199 · a4.xml · derivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-01-21 F1 · derivative.exercise_date: This option was granted on January 22, 2019 and vests over one year in twelve equal monthly installments, commencing on February 22, 2019. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:16 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 14,000 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001070081-18-000024 · wf-form4_151518700209317.xml · derivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-01-02 F1 · derivative.exercise_date: This option was granted on January 3, 2018 and vests over one year in twelve equal monthly installments, commencing on February 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 00:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 12,000 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001070081-17-000038 · wf-form4_148366225449037.xml · derivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-01-02 F1 · derivative.exercise_date: This option was granted on January 3, 2017 and vests over one year in twelve equal monthly installments, commencing on February 3, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.